Infliximab (a drug for clinical treatment of inflammatory bowel disease) can attenuate the damage of intestinal mucosa caused by TNF‐α and TGF‐β, and SB431542, an inhibitor of TGF‐β, can inhibit this effect [87]. Here, TGFB1 is linked to inflammatory bowel disease.